Text Size

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


  • 2024
  • International Journal of Molecular Sciences
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Ophthalmology Innovation Center, Santen Inc., Emeryville, 94608, CA, United States; Institute of Ophthalmology, University College London (UCL), London, EC1V 9EL, United Kingdom; Department of Ophthalmology, Imperial College of Science and Technology, St. Mary’s Campus, London, W2 1PG, United Kingdom; Department of Ophthalmology, Eye-ACP Duke-National University of Singapore Medical School, Singapore, 119228, Singapore; Singapore Eye Research Institute (SERI), Singapore, 168751, Singapore; Department of Pharmacy Sciences, Creighton University, Omaha, 68178, NE, United States; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, 77004, TX, United States; Department of Pharmacology & Neuroscience, North Texas Eye Research Institute (NTERI), University of North Texas Health Science Center, Fort Worth, 76107, TX, United States; Department of Ophthalmology and Center for Translational Vision Research, University of California, Irvine, 92617, CA, United States; Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Nara, 630-0101, Japan

Related Publications

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study

Panarelli J.F., Moster M.R., Garcia-Feijoo J., Flowers B.E., Baker N.D., Barnebey H.S., Grover D.S., Khatana A.K., Lee B., Nguyen T., Stiles M.C., Sadruddin O., Khaw P.T., Vold S., McFarland M., Stiles M., Stechschulte A., Strom A., Reynolds A., Noecker R., Thimons J., Khaimi M., Allen E., Sarkisian S., Barnebey H., Golez E., Feldman R., Bell N., Blieden L., Cantor L., WuDunn D., Catoira-Boyle Y., Chen H., Evans J., Martin E., Sozeri Y., Srivastava V., Wise R., Schwartz K., Grover D., Butler M., Emanuel M., Fellman R., Godfrey D., Smith O., Kornmann H., Khatana A., Hagee D., Kuhlman B., Zink J., Moster M., Dale E., Pro M., Baker D., Chambers M., Lehmann D., Caprioli J., Francis B., Giaconi J., Law S., Nouri-Mahdavi K., Coleman A., Flynn W., Rashid E., Reilly C., Rice R., Sidoti P., Panarelli J., Garg R., Tania Tai T.Y., Vinod K., Harizman N., Ritch R., Reiss G., Dewan V., Patel S., Sorenson C., Larsen C., Samuelson T., Hansen M., Barth T., Blakstad A., Buboltz M., Fahmy A., Fahmy M., Montealegre K., Mizener M., Whitted P., Lim M., Brandt J., Baik A., Jiang A., Brown S.V.L., Breunig A.C., Gorla M.S.R., Riss I., Feijoo G., Mendez Hernandez C., Martinez de la Casa J., Dupré Pelaez M., Fernandez Vidal A., García Sáenz S., Morales Fernandez L., Sáenz Francés F., Santos Bueso E., Perucho Gonzalez L., Beckers H.J.M., Kujovic S., Nardi M., Maglionico M.N., Nasini F., Passani A., Strouthidis N., Barton K., Clarke J., Gazzard G., Jayaram H., Khaw P., Papadopoulos M., Puertas R., Toth M., Lunt D., Triolo G., Kam R., Levine J., Flowers B., Nair U., Simmons S., Pokabla M., INN005 Study Group


Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)

Bacharach J., Brubaker J.W., Evans D.G., LU F., Odani-Kawabata N., Yamabe T., Wirta D.L.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022